Venue: Centre Broca
National Institute of Drug Abuse
Invited by Marc Auriacombe
New targets and medications for stimulant use disorders
The prevalence of stimulant use disorders (StUD) is increasing worldwide. In the United States, stimulants are associated with about 40% of the drug overdose deaths. Unfortunately, there are no medications approved by regulatory agencies to treat StUD, including stimulant overdose. The US National Institute on Drug Abuse (NIDA) has intensified its efforts to discover and develop medication to tear these conditions. The purpose of the presentation is to provide an overview of the new pharmacological targets and new medications that NIDA is currently investigating to treat StUD and overdose.
Dr. Montoya is the Clinical Director of the Division of Therapeutics and Medical Consequences (DTMC) of the National Institute on Drug Abuse (NIDA) and Chair of the National Institutes of Health (NIH) HEAL Initiative in Therapeutics Development for Opioid and Stimulant Use Disorders. He leads a large program of research that supports the development of pharmacological and non-pharmacological treatments for Substance Use Disorders (SUDs). He has an M.D. and specialized in psychiatrist from the University of Antioquia (Colombia) and has a Master’s in Public Health (M.P.H.) from Johns Hopkins University. He completed a Post-Doctoral Fellowship at the Intramural Research Program of NIDA and was the Director of the Practice Research Network of the American Psychiatric Association. He has published extensively in the areas of etiology, prevention, treatment, and medical consequences of SUDs. He is the editor of a book summarizing the science on biologics (vaccines, monoclonal antibodies, and enzymes) to treat SUDs and of another book focusing on the science of Cannabis Use Disorders. He has received numerous awards including the NIH Director’s Award and the Michael Morrison Award from the College on Problems of Drug Dependence (CPDD).